Bai James, Varghese Jerrin, Jain Rajan
Department of Radiology, New York University Langone Health, New York, NY.
Department of Neurosurgery, New York University Langone Health, New York, NY.
Top Magn Reson Imaging. 2020 Apr;29(2):71-82. doi: 10.1097/RMR.0000000000000234.
Recent advances in the understanding of the genetic makeup of gliomas have led to a paradigm shift in the diagnosis and classification of these tumors. Driven by these changes, the World Health Organization (WHO) introduced an update to its classification system of central nervous system (CNS) tumors in 2016. The updated glioma classification system incorporates molecular markers into tumor subgrouping, which has been shown to better correlate with tumor biology and behavior as well as patient prognosis than the previous purely histology-based classification system. Familiarity with this new classification scheme, the individual molecular markers, and corresponding imaging findings is critical for the radiologists who play an important role in diagnostic and surveillance imaging of patients with CNS tumors. The goals of this article are to review these updates to the WHO classification of CNS tumors with a focus on adult gliomas, provide an overview of key genomic markers of gliomas, and review imaging features pertaining to various genomic subgroups of adult gliomas.
近年来,对胶质瘤基因组成的认识取得了进展,这导致了这些肿瘤诊断和分类的范式转变。在这些变化的推动下,世界卫生组织(WHO)于2016年对其中枢神经系统(CNS)肿瘤分类系统进行了更新。更新后的胶质瘤分类系统将分子标志物纳入肿瘤亚组划分,与之前单纯基于组织学的分类系统相比,已证明其与肿瘤生物学、行为以及患者预后的相关性更好。熟悉这一新的分类方案、各个分子标志物及相应的影像学表现,对于在CNS肿瘤患者诊断和监测成像中发挥重要作用的放射科医生至关重要。本文的目的是回顾WHO对CNS肿瘤分类的这些更新,重点关注成人胶质瘤,概述胶质瘤的关键基因组标志物,并回顾与成人胶质瘤各种基因组亚组相关的影像学特征。